

Figure S1. MTT assay following treatment of parental PC cell lines (MIAPaCa-2) and gemcitabine-resistant cells (GR3) with gemcitabine. *P<0.01. PC, pancreatic cancer.




Figure S2. Confirmation of circ72309 overexpression and knockdown. circRNA, circular RNA.




Figure S3. Changes in miR-1234 and miR-1225-3p levels. *P<0.01. miR, microRNA.




Figure S4. Changes in the serum levels of circ72309 between pre-treatment and post-operative circ72309 levels. Data were compared using a paired t-test. n=13. circRNA, circular RNA.




Figure S5. Effect of NAC (a ROS scavenger) on *CDA* levels between GR_circ72309OE (control) and GR_circ72309OE_+ NAC. * $P < 0.01$. NAC, N-acetylcysteine; ROS, reactive oxygen species.




Figure S6. Schema of the present study. dFdC, 2',2'-Difluoro-2'-deoxycytidine; dFdU, 2',2'-Difluoro-2'-deoxyuridine; dFdCTP, 2',2'-Difluoro-2'-deoxycytidine-5'-triphosphoric acid; hENT1, human equilibrative nucleoside transporter 1; CDA, cytidine deaminase; ROS, reactive oxygen species; ATP, adenosine triphosphate.

